

November 4, 2014

Matrix, Company Name 3 - D Ltd. Address 3-2-4, Kojimachi, Chiyoda, Tokyo President Kentaro Takamura Code Number 7777 Contact Director Tomoyuki Arai +81 3 (3511)3440 \mathbf{T} \mathbf{E} \mathbf{L}

<u>Absorbable Hemostat "PuraStat®"</u> Commencement of clinical use in Chile

The 3-D Matrix group has been working on clinical use of absorbable hemostat "PuraStat®" in Europe since obtaining CE marking for the product on January 14, 2014.

Today, the company received an approval of the hospital to announce that clinical use of the product has commenced at the Hospital San Borja-Arriaran in Chile on October 30th, 2014.

Cristian Baeza, M.D., who is the Chief of Department of Cardiovascular Surgery of Hospital San Borja-Arriaran and Clinica Las Condes, which is a flagship hospital in Chile, conducted the clinical use to control bleeding during a surgical procedure.

With the commencement of clinical use, the company aims to further promote clinical use of PuraStat® in our core Latin American markets, and expand the distribution of the product through an agreement with a marketing partner.

This announcement does not influence the earning forecast of the company at this moment.